NCT07710885 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07710885
Title	Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer (FOENIX-BTC)
Acronym	FOENIX-BTC
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Taiho Pharmaceutical Co., Ltd.
Indications	intrahepatic cholangiocarcinoma biliary tract cancer extrahepatic bile duct adenocarcinoma gallbladder adenocarcinoma adenosquamous gallbladder carcinoma
Therapies	Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine Cisplatin + Futibatinib + Gemcitabine + Zimberelimab
Age Groups:	senior \| adult
Covered Countries	AUS

NCT07710885
Clinical Trial Detail